Comparisons of the Efficacy of a Jak1/2 Inhibitor (AZD1480) with a VEGF Signaling Inhibitor (Cediranib) and Sham Treatments in Mouse Tumors Using DCE-MRI, DW-MRI, and Histology

Comparisons of the Efficacy of a Jak1/2 Inhibitor (AZD1480) with a VEGF Signaling Inhibitor (Cediranib) and Sham Treatments in Mouse Tumors Using DCE-MRI, DW-MRI, and Histology

Jak1/2 inhibition suppresses STAT3 phosphorylation that is characteristic of many cancers. Activated STAT3 promotes the transcription of factors that enhance tumor growth, survival, and angiogenesis. AZD1480 is a novel small molecule inhibitor of Jak1/2, which is a key mediator of STAT3 activation....

Full description

Bibliographic Details
Main Authors: Mary E. Loveless, Deborah Lawson, Michael Collins, Murali V. Prasad Nadella, Corinne Reimer, Dennis Huszar, Jane Halliday, John C. Waterton, John C. Gore, Thomas E. Yankeelov
Format: Article
Language:English
Published: Elsevier 2012-01-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558612800789

Internet

http://www.sciencedirect.com/science/article/pii/S1476558612800789

Similar Items